The Hangzhou Medical Port of Yimao Medical Park is here!

Looking at China's gene therapy industry, the start-up time is short, but the company's layout is fast, and innovative results are emerging

From 14:00-16:15 pm on April 22,

Live broadcast preview

Etrade Medical took you to Hangzhou Medical Port, which is a representative biopharmaceutical industry gathering place, and joined hands with Hangzhou Medical Port and Duoning Bio to launch an online live broadcast of "Frontier Progress in Gene Therapy" on April 22.

host

Huating

A pharmaceutical analyst at Caitong Securities Research Institute, his main research direction is the field of innovative drugs and medical services

Interviews/Speakers

Wu Haoquan

He graduated from Fudan University in 2000, and worked as a post-doctoral researcher at UCLA and Harvard Medical School.

Topic:

Interviews/Speakers

Xu Songlin

Xu Songlin, Executive Vice President of Zhejiang Haichang Biomedical Technology Co.

Speech Topic:

Interview guests

Xiangsheng Liu is a research fellow at the Institute of Basic Medicine and Oncology, Chinese Academy of Sciences

In 2009 and 2014, he received his BS and PhD degrees from the Department of Polymer Science, Zhejiang University, respectively

At present, he is mainly engaged in the research of anti-tumor nucleic acid aptamer-targeted drugs, mRNA nucleic acid vaccines, nano-drugs, tumor immunotherapy, and nano-surface interface biological effects

Speakers

Gu Hongfeng Vice President Duoning
Biotechnology

Mr.
Gu Hongfeng majored in Biochemistry and Molecular Biology
.
Served as Vice President of Dorning Bio and was fully responsible for managing projects and sales for key clients in the biopharmaceutical and cell therapy fields
.
He has more than ten years of rich experience in the biopharmaceutical industry, especially in the field of cell gene therapy
.
He has worked in Shanghai Institute of Biological Products, Wisdom Chemical, Pall and other companies successively, responsible for the establishment of stem cell lines and functional exploration, focusing on drug development and tracking of CGT market customers, leading the team to grow rapidly and achieve considerable results
.

Speech topic:
New breakthroughs in gene therapy process solutions,
technology and progress in the field of gene therapy,
gene therapy process route and challenges
and recommendations of Doning platform solutions

About Park Tour Activities

The Yimao Medical Park Tour series is that Yimao Medical has entered the country's leading bio-industrial parks around topics related to biological drug research and development and technology.
Enterprises build a platform for exchanges and cooperation, break down geographical barriers, and further strengthen the exchanges between enterprises in various biopharmaceutical industrial parks in China, thereby promoting the vigorous development of China's biopharmaceutical industry
.

About Hangzhou Medical Port

Hangzhou Pharmaceutical Port is the core area for the development of the biomedical industry in Hangzhou and even in Zhejiang Province.
It has been selected as the province's "10,000 mu and 100 billion" new industrial platform, the province's industrial innovation service complex, the first batch of healthy Zhejiang action demonstration models, and the first batch of provincial "new stars" The list of industrial clusters has won the title of "Zhejiang Provincial Characteristic Town" and the "Strongest Industrial Town" in Hangzhou
.
At present, more than 1,400 biopharmaceutical companies such as Tianjing Bio, WuXi Biologics, and Huahai Pharmaceutical have gathered.
Seven of the world's top 10 pharmaceutical companies, including Merck, Abbott, and Johnson & Johnson, have settled down, and 17 companies have been selected as quasi-unicorns.
On the list, there are 19 listed companies and key companies to be listed.
In 2021, biopharmaceutical companies will achieve revenue of 45 billion yuan, a year-on-year increase of 12%
.
There are more than 500 high-level talents, including 161 overseas leading talents, accounting for 50% of the total number of industries in the region
.
It has landed on 29 high-level platforms, including the Institute of Medicine of the Chinese Academy of Sciences, the Institute of Intelligent Innovative Drugs of Zhejiang University, and the Biomedical Innovation Public Service Platform of the Provincial Food and Drug Administration, building a new "chain + cluster" development model
.

About Donning Bio

Founded in 2005, Shanghai Duoning Biotechnology Co.
, Ltd.
(abbreviation: Duoning Bio) is a leading provider of bioprocessing solutions in China, dedicated to the development of high-quality, high-efficiency serum-free, personalized, chemically defined cell cultures base and animal cell culture processes; research and development and production of disposable products, bioreactors, filtration separation, purification packing, laboratory series products for biopharmaceutical processes, and provide formula production, process optimization and verification, Testing and verification and other supporting services
.

Participate in registration

Event rewards
forward posters, enter the group to win exquisite prizes~

Pre-meeting interaction:
forward the poster to the circle of friends + copywriting screenshots or forward 5 industry groups + copywriting screenshots, send to Xiaoyi@trademedical, you will get a Luckin 35 yuan coffee coupon! Quantities are limited, first come first served!

Interaction during the meeting: Interact
with the host in the live room to win the following prizes

Forward the poster: